fda compounding semaglutide crackdown november 2025 New Insights,removed semaglutide in February 2025

The FDA has intensified its scrutiny of compounding pharmacies involved with semaglutide and other GLP-1 drugs, leading to a significant crackdown that is reshaping the market. As of November 2025, the FDA's regulatory stance has become increasingly clear, with a focus on ensuring patient safety and preventing misleading marketing. This escalating enforcement is particularly relevant for compounding semaglutide and related compounded medications.

The FDA's concerns stem from several key areas. One primary issue is the marketing of unapproved GLP-1 drugs, often falsely labeled "for research" but intended for human consumption. The agency has issued warning letters to companies engaging in such practices, highlighting that claims must be accurate and scientifically supported. This pushback against misleading marketing is a central theme in the FDA's 2025 Peptide Crackdown Explained.

A significant driver for the FDA's increased enforcement has been the removal of semaglutide and tirzepatide from the FDA's drug shortages list. Semaglutide was officially removed from the shortage list in February 2025, and tirzepatide followed in December 2024. With the apparent resolution of supply chain issues for the approved versions of these drugs, the FDA is now focusing on compounding practices that may no longer be justified by the initial need to fill supply gaps. This shift in policy has led to a direct crackdown on companies that continued to provide compounded versions of these drugs after they were no longer on the shortage list.

The FDA has been actively communicating its policies to compounders. In April 2025, the FDA clarified policies for compounders, emphasizing that certain conditions must be met for compounded drugs to qualify for exemptions under sections 503A and 503B of the Food, Drug, and Cosmetic Act. This clarification is crucial for understanding the legal boundaries of compounding in the current regulatory environment.

Furthermore, the FDA has taken action against companies that were making compounded semaglutide and tirzepatide products. In September 2025, the FDA issued over 55 warning letters to online sellers of compounded versions of glucagon-like peptide-1 (GLP-1) drugs. This targeted action underscores the agency's commitment to addressing non-compliance.

The FDA's stance is that compounding should not be used to circumvent approved drug pathways. For instance, larger outsourcing pharmacies making compound versions of drugs like Zepbound were given deadlines to cease production, with state-licensed pharmacies also being instructed to stop making such preparations. This indicates a broader move to restrict ingredients used in mass-marketed compounded GLP-1 drugs and crack down on deceptive advertising.

The impact of these actions is significant. Reports indicate that the FDA has received over 500 reports of serious side effects tied to compounded semaglutide and tirzepatide, highlighting the potential safety risks associated with these products. The FDA's actions are seen by some as overdue, potentially leading to a significant shift for the estimated 1.5 million users of compounded medications.

In summary, the FDA compounding semaglutide crackdown in November 2025 signifies a heightened regulatory focus on compounded GLP-1 drugs. The FDA's efforts are aimed at ensuring drug integrity, patient safety, and truthful marketing, particularly as approved versions of semaglutide and tirzepatide are no longer in short supply. This evolving landscape requires careful attention from compounders, manufacturers, and patients alike, with the FDA's policies and enforcement actions setting the direction for the industry. The FDA also intends to take action against non-FDA-approved compounded drugs and is reaffirming strict regulations amid GLP-1 market dynamics.